David Didio
About David Didio
David Didio is a Senior Principal Scientist at Bristol Myers Squibb in Summit, New Jersey, with extensive experience in process development and characterization across multiple pharmaceutical companies.
Company
David Didio currently works at Bristol Myers Squibb as a Senior Principal Scientist in Summit, New Jersey, United States. His role involves leading scientific research and development projects within the organization. His previous experience includes positions at Celgene, Shire, Ambrx, and Allergan, providing him with a diverse background in the pharmaceutical and biotechnology industries.
Title
David Didio holds the title of Senior Principal Scientist. His professional history demonstrates a consistent upward trajectory in various scientific roles, showcasing his expertise and leadership in the field.
Education and Expertise
David Didio studied at the State University of New York Upstate Medical University, where he achieved a Master's degree in Pharmacology. He has implemented high throughput instrumentation for downstream process development and process characterization studies, and has expertise in process characterization and viral clearance studies. He is proficient in scripting and integrating analytical instrumentation for high throughput workflows, and has managed First-In-Human (FIH) programs to completion.
Professional Background
David Didio's career includes multiple roles in notable pharmaceutical companies. At Bristol Myers Squibb, he is a Senior Principal Scientist. From 2019 to 2021, he was a Principal Scientist at Celgene, and from 2017 to 2019, he served as a Senior Scientist at Celgene. Prior to that, he was a Senior Downstream Development Engineer at Shire from 2015 to 2017, and a Scientist in Process Development, CMC at Ambrx from 2013 to 2015. His early career included roles as a Scientist and Sr. Professional at Allergan from 2008 to 2013, and as an Associate Scientist at Bristol-Myers Squibb from 2004 to 2008.
Achievements
David Didio has authored and reviewed sections for IND and BLA applications. He has managed programs externally with Contract Manufacturing Organizations (CMOs) and has successfully completed multiple First-In-Human (FIH) programs. His work has involved extensive collaboration with cross-functional teams, including analytical, upstream, and drug product development teams to support various program development activities.